A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft-versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)
Latest Information Update: 19 Mar 2025
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms MODULAATE
- Sponsors CSL Behring
Most Recent Events
- 17 Mar 2025 Planned End Date changed from 28 Sep 2031 to 18 Oct 2029.
- 17 Mar 2025 Planned primary completion date changed from 28 Mar 2031 to 30 Apr 2028.
- 12 Mar 2025 Planned End Date changed from 1 Mar 2027 to 28 Sep 2031.